A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

Trial Details

NCT ID
NCT06999187
Phase
PHASE1
Sponsor
Dren Bio
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Orlando, Florida, United States|28.53834,-81.37924
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Huntersville, North Carolina, United States|35.41069,-80.84285
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Histologically confirmed epithelial cancer of the following tumor types: breast (TNBC, HR+/HER2-/+BC), NSCLC, cervical, CRPC, PDAC, HNSCC, endometr…
  • Relapsed or refractory with at least 2 prior lines of therapy and for which no standard of care treatment options are available
  • Radiographically measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →